Immuneering Corporation Research and Development Expense
Immuneering Corporation (IMRX) reported Research and Development Expense of $14.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Immuneering Corporation research and development expense for the quarter ending 2026-06-30 was $14.00M, a 33.89% increase year-over-year.
- Immuneering Corporation research and development expense for the quarter ending 2026-03-31 was $10.65M, a 7.20% decline year-over-year.
- Immuneering Corporation research and development expense for the quarter ending 2025-12-31 was $9.25M, a 37.71% decline year-over-year.
- Immuneering Corporation research and development expense for the quarter ending 2025-09-30 was $10.87M, a 3.42% decline year-over-year.
- Immuneering Corporation research and development expense for fiscal 2025 was $42.05M, a 12.33% decline from fiscal 2024.
- Immuneering Corporation research and development expense for fiscal 2024 was $47.96M, a 15.23% increase from fiscal 2023.
- Immuneering Corporation research and development expense for fiscal 2023 was $41.62M, a 14.77% increase from fiscal 2022.
- Immuneering Corporation research and development expense for fiscal 2022 was $36.27M, a 36.65% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.00M 10-Q · filed 2026-08-05 | $24.64M 10-Q · filed 2026-08-05 | $33.90M derived: sum of 3 quarters · filed 2026-08-05 | $44.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.65M 10-Q · filed 2026-05-15 | $19.90M derived: sum of 2 quarters · filed 2026-05-15 | $30.77M derived: sum of 3 quarters · filed 2026-05-15 | $41.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $20.12M derived: sum of 2 quarters · filed 2026-03-06 | $30.58M derived: sum of 3 quarters · filed 2026-08-05 | $42.05M 10-K · filed 2026-03-06 |
| 2025-09-30 | $10.87M 10-Q · filed 2025-11-12 | $21.32M derived: sum of 2 quarters · filed 2026-08-05 | $32.79M 10-Q · filed 2025-11-12 | $47.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.45M 10-Q · filed 2026-08-05 | $21.93M 10-Q · filed 2026-08-05 | $36.78M derived: sum of 3 quarters · filed 2026-08-05 | $48.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $11.47M 10-Q · filed 2026-05-15 | $26.33M derived: sum of 2 quarters · filed 2026-05-15 | $37.58M derived: sum of 3 quarters · filed 2026-05-15 | $48.23M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $26.11M derived: sum of 2 quarters · filed 2026-03-06 | $36.76M derived: sum of 3 quarters · filed 2026-03-06 | $47.96M 10-K · filed 2026-03-06 |
| 2024-09-30 | $11.25M 10-Q · filed 2025-11-12 | $21.90M derived: sum of 2 quarters · filed 2025-11-12 | $33.11M 10-Q · filed 2025-11-12 | $45.02M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $10.65M 10-Q · filed 2025-08-13 | $21.85M 10-Q · filed 2025-08-13 | $33.76M derived: sum of 3 quarters · filed 2025-08-13 | $43.81M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $11.20M 10-Q · filed 2025-05-05 | $23.11M derived: sum of 2 quarters · filed 2025-05-05 | $33.16M derived: sum of 3 quarters · filed 2025-05-05 | $42.62M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $21.96M derived: sum of 2 quarters · filed 2025-03-20 | $31.41M derived: sum of 3 quarters · filed 2025-03-20 | $41.62M 10-K · filed 2025-03-20 |
| 2023-09-30 | $10.05M 10-Q · filed 2024-11-13 | $19.50M derived: sum of 2 quarters · filed 2024-11-13 | $29.71M 10-Q · filed 2024-11-13 | $39.59M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $9.45M 10-Q · filed 2024-08-06 | $19.66M 10-Q · filed 2024-08-06 | $29.54M derived: sum of 3 quarters · filed 2024-08-06 | $38.90M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $10.21M 10-Q · filed 2024-05-07 | $20.08M derived: sum of 2 quarters · filed 2024-05-07 | $29.45M derived: sum of 3 quarters · filed 2024-05-07 | $37.43M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $19.24M derived: sum of 2 quarters · filed 2024-03-01 | $27.22M derived: sum of 3 quarters · filed 2024-03-01 | $36.27M 10-K · filed 2024-03-01 |
| 2022-09-30 | $9.36M 10-Q · filed 2023-11-09 | $17.34M derived: sum of 2 quarters · filed 2023-11-09 | $26.40M 10-Q · filed 2023-11-09 | $34.35M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $7.98M 10-Q · filed 2023-08-03 | $17.03M 10-Q · filed 2023-08-03 | $24.99M derived: sum of 3 quarters · filed 2023-08-03 | $31.20M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $9.06M 10-Q · filed 2023-05-04 | $17.01M derived: sum of 2 quarters · filed 2023-05-04 | $23.22M derived: sum of 3 quarters · filed 2023-05-04 | $30.21M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $14.16M derived: sum of 2 quarters · filed 2023-03-06 | $21.15M derived: sum of 3 quarters · filed 2023-03-06 | $26.54M 10-K · filed 2023-03-06 |
| 2021-09-30 | $6.21M 10-Q · filed 2022-11-10 | $13.20M derived: sum of 2 quarters · filed 2022-11-10 | $18.59M 10-Q · filed 2022-11-10 | $23.48M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $6.99M 10-Q · filed 2022-08-10 | $12.38M 10-Q · filed 2022-08-10 | $17.27M derived: sum of 3 quarters · filed 2022-08-10 | $21.34M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $5.39M 10-Q · filed 2022-05-10 | $10.28M derived: sum of 2 quarters · filed 2022-05-10 | $14.35M derived: sum of 3 quarters · filed 2022-05-10 | $17.57M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $8.96M derived: sum of 2 quarters · filed 2022-03-10 | $12.18M derived: sum of 3 quarters · filed 2022-03-10 | $15.00M 10-K · filed 2022-03-10 |
| 2020-09-30 | $4.07M 10-Q · filed 2021-11-09 | $7.29M derived: sum of 2 quarters · filed 2021-11-09 | $10.11M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $3.22M 10-Q · filed 2021-09-09 | $6.04M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |